IOL Chemicals & Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• IOL Chemicals & Pharmaceuticals Ltd reported a 6.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.7%.
• Its expenses for the quarter were up by 0.7% QoQ and 12.9% YoY.
• The net profit increased 158.3% QoQ and increased 69.2% YoY.
• The earnings per share (EPS) of IOL Chemicals & Pharmaceuticals Ltd stood at 1.81 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

IOL Chemicals & Pharmaceuticals Ltd is a well-established company in the chemicals and pharmaceuticals industry. The company is primarily engaged in the manufacturing and sale of chemical and pharmaceutical products. IOL Chemicals is known for its production of active pharmaceutical ingredients (APIs) and specialty chemicals. The company serves a broad range of sectors within this industry, supplying essential components for pharmaceutical manufacturing and other chemical-related applications. Recent developments in the company or significant strategic shifts are not available in the provided data, thus specific current events or changes cannot be detailed.

Revenue

In Q4FY26, IOL Chemicals & Pharmaceuticals Ltd reported a total income of ₹621.29 crores. This represents a 6.1% increase quarter-over-quarter (QoQ) from ₹585.68 crores in Q3FY26 and a 16.7% increase year-over-year (YoY) from ₹532.31 crores in Q4FY25. The growth in revenue indicates a positive trajectory in the company’s ability to generate income in the recent quarter compared to both the previous quarter and the same quarter in the previous year. The consistent increase in income could be attributed to the company's operational strategies or market conditions, but specific reasons are not detailed in the data provided.

Profitability

The company's profitability metrics for Q4FY26 show notable improvement. The profit before tax (PBT) for this quarter was ₹70.81 crores, which is a significant increase of 157.0% QoQ from ₹27.55 crores in Q3FY26, and a 58.4% increase YoY from ₹44.70 crores in Q4FY25. After accounting for taxes, the profit after tax (PAT) rose to ₹53.16 crores, marking a 158.3% QoQ increase from ₹20.58 crores and a 69.2% YoY increase from ₹31.42 crores. These figures indicate a strong improvement in the company’s profitability over both the previous quarter and the corresponding quarter of the previous year. The effective tax for the quarter was ₹17.65 crores, which increased by 153.2% QoQ and 32.9% YoY.

Operating Metrics

The earnings per share (EPS) for IOL Chemicals & Pharmaceuticals Ltd in Q4FY26 was reported at ₹1.81, showing a substantial increase of 158.6% QoQ from ₹0.70 and a 69.2% increase YoY from ₹1.07. The total expenses for the company in Q4FY26 were ₹550.48 crores, which is a 0.7% increase from ₹546.92 crores in Q3FY26, and a 12.9% increase from ₹487.61 crores in Q4FY25. The relatively modest increase in expenses compared to income suggests efficient cost management, although specific strategies or actions undertaken by the company to achieve this are not provided in the data. The operating metrics reflect the company’s ability to effectively manage its resources and deliver enhanced value per share to its shareholders over the specified periods.